Establishment of a treatment for advanced hepatocellular carcinoma using a tri-functional specific antibody

• Project/Area Number: 21590853
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Gastroenterology
• Research Institution: Sapporo Medical University
• Principal Investigator: SASAKI Shigeru 札幌医科大学, 医学部, 講師 (10305229)
• Co-Investigator(Kenkyū-buntansha): YAMAMOTO Hiroyuki 札幌医科大学, 医学部, 講師 (40332910) ; IMAI Kohzoh 東京大学, 医科学研究所, 教授 (60117603) ; SHINOMURA Yasuhisa 札幌医科大学, 医学部, 教授 (90162619)
• Project Period (FY): 2009 – 2011
• Project Status: Completed (Fiscal Year 2011)
• Budget Amount: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000); Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000); Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000); Fiscal Year 2009: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
• Keywords: 肝臓学 / 肝癌 / 抗体治療 / 分子標的 / 分子改変 / 癌

Research Abstract

For advanced hepatocellular carcinoma has not been established at all treatments, we' ve been doing this research for the purpose of development of therapeutic antibodies as ideal therapeutic agents. We have shown that interferon(IFN)-α/βinduced the up-regulation of fibroblast growth factor receptor-1(FGFR-1) expression in several human liver cancer cells. Based on this result, we have created several anti-FGFR-1 monoclonal antibodies(MoAbs). We revealed that the efficacy of combined treatment with anti-FGFR-1 MoAb and interferon-α/βin human liver cancer cells in vitro and in vivo. The aim of this antibody therapy is more potent anti-cancer effects, we performed molecular alterations of this antibody, and established a tri-functional specific antibody in this study.

Research Products

• [Journal Article] Interferon-α/βand anti-fibroblast growth factor receptor 1 monoclonal antibody suppress hepatic cancer cells in vitro and in vivo (2011)
  • Author(s): Sasaki S, Ishida T, Toyota M, Ota A, Suzuki H, Takaoka A, Yasui H, Yamamoto H, Takagi H, Maeda M, Seito T, Tsujisaki M, Shinomura Y, Imai K
  • Journal Title: PLoS One
  • Peer Reviewed
• [Journal Article] Interferon-α/β and anti-fibroblast growth factor receptor 1 monoclonal antibody suppress hepatic cancer cells in vitro and in vivo (2011)
  • Author(s): Sasaki S., et al
  • Journal Title: PLoS One Volume: 6 Issue: 5 Pages: e19618-e19618
  • DOI: 10.1371/journal.pone.0019618
  • Peer Reviewed
• [Presentation] 肝細胞がんに対するIFNおよび抗FGFR1抗体併用新規治療法の開発 (2011)
  • Author(s): 佐々木茂
  • Organizer: 第97回日本消化器病学会総会
  • Place of Presentation: 東京
  • Year and Date: 2011-05-13
• [Presentation] 肝細胞がんに対するIFNおよび抗FGFR1抗体を用いた新規抗体治療法の開発 (2010)
  • Author(s): 佐々木茂
  • Organizer: 第48回日本癌治療学会学術集会
  • Place of Presentation: 京都
  • Year and Date: 2010-10-29
• [Presentation] 肝細胞癌に対するIFNおよび抗FGFR1抗体を用いた新規抗体治療法の開発 (2010)
  • Author(s): 佐々木茂
  • Organizer: 第48回日本癌治療学会学術集会
  • Place of Presentation: 国立京都国際会館(京都)
  • Year and Date: 2010-10-29
• [Presentation] 肝細胞がんに対するIFNおよび抗FGFR1抗体を用いた新規抗体療法の開発 (2010)
  • Author(s): 佐々木茂
  • Organizer: 第47日本消化器免疫学会総会
  • Place of Presentation: 大津
  • Year and Date: 2010-07-08
• [Presentation] 肝細胞がんに対するIFNおよび抗FGFR1抗体を用いた新規抗体治療法の開発 (2010)
  • Author(s): 佐々木茂
  • Organizer: 第47回日本消化器免疫学会総会
  • Place of Presentation: 大津プリンスホテル(大津)
  • Year and Date: 2010-07-08
• [Presentation] FGFR1を標的とした肝細胞がんに対する新規抗体治療法の開発 (2010)
  • Author(s): 佐々木茂
  • Organizer: 第26回日本DDS学会学術集会
  • Place of Presentation: 大阪
  • Year and Date: 2010-06-17
• [Presentation] FGFR1を標的とした肝細胞がんに対する新規抗体治療法の開発 (2010)
  • Author(s): 佐々木茂
  • Organizer: 第26回日本DDS学会学術集会
  • Place of Presentation: 大阪国際交流センター(大阪)
  • Year and Date: 2010-06-17
• [Presentation] 消化器がんに対する改造抗体の作製 (2009)
  • Author(s): 佐々木茂
  • Organizer: 第25回日本DDS学会学術総会
  • Place of Presentation: 東京ドームホテル(東京)
  • Year and Date: 2009-07-03